G
Gerd Ritter
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 165
Citations - 16107
Gerd Ritter is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Antigen & Antibody. The author has an hindex of 67, co-authored 165 publications receiving 15272 citations. Previous affiliations of Gerd Ritter include Centre Hospitalier Universitaire de Sherbrooke & Ludwig Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
Eiichi Sato,Sara H. Olson,Jiyoung Ahn,Brian N. Bundy,Hiroyoshi Nishikawa,Feng Qian,Achim A. Jungbluth,Denise Frosina,Sacha Gnjatic,Christine B. Ambrosone,James L. Kepner,Tosin Odunsi,Gerd Ritter,Shashikant Lele,Yao-Tseng Chen,Haruo Ohtani,Lloyd J. Old,Kunle Odunsi +17 more
TL;DR: It is concluded that intraepithelial CD8+ TILs and a high CD8-/Treg ratio are associated with favorable prognosis in epithelial ovarian cancer.
Journal ArticleDOI
Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.
P. O. Livingston,G Y Wong,S Adluri,Y Tao,M Padavan,R Parente,C Hanlon,Michele Jones Calves,F Helling,Gerd Ritter +9 more
TL;DR: A double-blind randomized trial to confirm the previous finding that patients with antibodies against the melanoma differentiation antigen GM2 have an improved prognosis and demonstrate clinical benefit from GM2 antibody induction, and to show a statistically significant improvement in disease-free interval or survival for patients treated with GM2/BCG vaccines.
Journal ArticleDOI
NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Ian F. Hermans,Jonathan D. Silk,Uzi Gileadi,Mariolina Salio,Bini Mathew,Gerd Ritter,Richard R. Schmidt,Adrian L. Harris,Lloyd Old,Vincenzo Cerundolo +9 more
TL;DR: iNKT cells exert a significant influence on the efficacy of immune responses to soluble Ag by modulating DC function, and these responses resisted challenge with OVA-expressing tumors.
Journal ArticleDOI
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.
Elke Jäger,Sacha Gnjatic,Yasuhiro Nagata,Elisabeth Stockert,Dirk Jäger,Julia Karbach,Antje Neumann,Julia Rieckenberg,Yao-Tseng Chen,Yao-Tseng Chen,Gerd Ritter,Eric W. Hoffman,Michael Arand,Lloyd J. Old,Alexander Knuth +14 more
TL;DR: It is demonstrated that primary NY-ESO-1-specific CD8+ T-cell responses can be induced by intradermal immunization with NY-Eso-1 peptides, and that immunized patients may have the potential to alter the natural course of NY- ESO- 1-expressing tumors.
Journal ArticleDOI
Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
E Jäger,Yasuhiro Nagata,Sacha Gnjatic,Hisashi Wada,Elizabeth Stockert,Julia Karbach,P R Dunbar,Sang-Yull Lee,Achim A. Jungbluth,Dirk Jäger,Michael Arand,Gerd Ritter,Vincenzo Cerundolo,Bo Dupont,Yao-Tseng Chen,Lloyd J. Old,Alexander Knuth +16 more
TL;DR: NY-ESO-1 ELISPOT and tetramer assays with excellent sensitivity, specificity, and reproducibility have been developed and found to correlate with cytotoxicity assays, providing the basis for standardized monitoring of T cell responses in patients receiving NY-ESo-1 vaccines.